Cargando…

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure

Three major cardiovascular outcome trials (CVOTs) with a new class of antidiabetic drugs - sodium-glucose cotransporter 2 (SGLT2) inhibitors (EMPA-REG OUTCOME trial with empagliflozin, CANVAS Program with canagliflozin, DECLARE-TIMI 58 with dapagliflozin) unexpectedly showed that cardiovascular outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grubić Rotkvić, Petra, Cigrovski Berković, Maja, Bulj, Nikola, Rotkvić, Luka, Ćelap, Ivana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415232/ https://www.ncbi.nlm.nih.gov/pubmed/32843930 http://dx.doi.org/10.4239/wjd.v11.i7.269

Ejemplares similares

The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities
por: Grubić Rotkvić, Petra, et al.
Publicado: (2021)

Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms
por: Mahečić, Davorka Herman, et al.
Publicado: (2020)

Perimyocarditis as First Manifestation of Systemic Lupus Erythematosus Successfully Treated with Heart Failure and Immunosuppressive Therapy
por: Ikić Matijašević, Marina, et al.
Publicado: (2023)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure
por: Nightingale, Brandon
Publicado: (2021)

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
por: Cavka, Luka, et al.
Publicado: (2021)

Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
por: Naito, Ryo, et al.
Publicado: (2021)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?
por: McDowell, Kirsty, et al.
Publicado: (2021)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Tamargo, Juan
Publicado: (2019)

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Tamargo, Juan
Publicado: (2019)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
por: Severino, Paolo, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
por: Fonseca-Correa, Jorge I., et al.
Publicado: (2021)

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
por: Uthman, Laween, et al.
Publicado: (2018)

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
por: Zelniker, Thomas A, et al.
Publicado: (2019)

Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure
por: Kambara, Takahiro, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
por: Kurczyński, Dominik, et al.
Publicado: (2022)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy
por: Altabas, Velimir, et al.
Publicado: (2015)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
por: BJORNSTAD, PETTER, et al.
Publicado: (2021)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
por: Rasalam, Roy, et al.
Publicado: (2021)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
por: Muneuchi, Jun, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
por: Choday, Silpa, et al.
Publicado: (2023)

Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction
por: Arslan, Kadem, et al.
Publicado: (2022)

The Mounting Evidence for Permissive Hypercreatinemia in Acute Heart Failure: Adding Sodium Glucose Cotransporter Inhibitors to the List
por: Macedo, Etienne, et al.
Publicado: (2023)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
por: Ji, Luxi, et al.
Publicado: (2023)

Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
por: Griffin, Matthew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mbp0345njadoa0s8dc4ko7hspi